AndersonN.L. & AndersonN.G. (2002). The human plasma proteome. History, character, and diagnostic prospects. Molecular & Cellular Proteomics1, 845–867.
4.
AndersonN.L., PolanskiM., PieperR., GatlinT., TirumalaiR.S., ConradsT.P., VeenstraT.D., AdkinsJ.N., PoundsJ.G., FaganR. & LobleyA. (2004). The human plasma proteome: A non-redundant list developed by combination of four separate sources. Molecular & Cellular Proteomics3, 311–326.
ShailerC. & CorrinK. (1999). Serum supply: Policies and controls operating in New Zealand. Developments in Biological Standardization99, 71–77.
7.
AsherD.M. (1999). Bovine sera used in the manufacture of biologicals: Current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies. Developments in Biological Standardization99, 41–44.
8.
DormontD. (1999). Transmissible spongiform encephalopathy agents and animal sera. Developments in Biological Standardization99, 25–34.
9.
EvenM.S., SanduskyC.B. & BarnardN.D. (2006). Serum-free hybridoma culture: Ethical, scientific and safety considerations. Trends in Biotechnology24, 105–108.
10.
WessmannS.J. & LevingsR.L. (1999). Benefits and risks due to animal serum used in cell culture production. Developments in Biological Standardization99, 3–8.
FujimotoB. (2002). Fetal bovine serum — Supply vs demand?Art to Science21, 1–4.
13.
JochemsC.E., van der ValkJ.B.F., StafleuF.R. & BaumansV. (2002). The use of fetal bovine serum: Ethical or scientific problem?ATLA30, 219–227.
14.
BrunnerD., FrankJ., ApplH., SchöfflH., PfallerW. & GstraunthalerG. (2010). Serum-free cell culture: The serum-free media interactive online database. ALTEX27, 53–62.
15.
van der ValkJ., BrunnerD., De SmetK., Fex SvenningsenÄ., HoneggerP., KnudsenL.E., LindlT., NorabergJ., PriceA., ScarinoM.L. & GstraunthalerG. (2010). Optimization of chemically defined cell culture media — Replacing fetal bovine serum in mammalian in vitro methods. Toxicology in Vitro24, 1053–1063.
16.
van der ValkJ., MellorD., BrandsR., FischerR., GruberF., GstraunthalerG., HellebrekersL., HyllnerJ., JonkerF.H., PrietoP., ThalenM. & BaumansV. (2004). The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicology in Vitro18, 1–12.
17.
BallsM., GoldbergA.M., FentemJ.H., BroadheadC.L., BurchR.L., FestingM.F.W., FrazierJ.M., HendriksenC.F.M., JenningsM., van der KampM.D.O., MortonD.B., RowanA.N., RussellC., RussellW.M.S., SpielmannH., StephensM.L., StokesW.S., StraughanD.W., YagerJ.D., ZurloJ. & van ZutphenB.F.M. (1995). The Three Rs: The way forward. The report and recommendations of ECVAM Workshop 11. ATLA23, 838–866.
18.
HodgsonJ. (1991). Checking the sources: The serum supply secret. Nature Biotechnology9, 1320–1324.
GstraunthalerG. (2003). Alternatives to the use of fetal bovine serum: Serum-free cell culture. ALTEX20, 275–281.
25.
BiebackK. (2013). Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfusion Medicine & Hemotherapy40, 326–335.
26.
RauchC., FeifelE., AmannE-M., SpötlH.P., SchennachH., PfallerW. & GstraunthalerG. (2011). Alternatives to the use of fetal bovine serum: Human platelet lysates as a serum substitute in cell culture media. ALTEX28, 305–316.
27.
RauchC., WechselbergerJ., FeifelE. & GstraunthalerG. (2014). Human platelet lysates successfully replace fetal bovine serum in adipose-derived adult stem cell culture. Journal of Advanced Biotechnology & Bioengineering2, 1–11.
28.
CoeckeS., BallsM., BoweG., DavisJ., GstraunthalerG., HartungT., HayR., MertenO.W., PriceA., SchechtmanL., StaceyG. & StokesW. (2005). Guidance on Good Cell Culture Practice. A report of the second ECVAM task force on Good Cell Culture Practice. ATLA33, 261–287.
